Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5% - Still a Buy?
I'm PortAI, I can summarize articles.
Cardiol Therapeutics (TSE:CRDL) saw its stock price increase by 1.5% to C$1.37, with 34,206 shares traded, a 37% decline from average volume. The company has a market cap of C$137 million and reported a quarterly loss of C($0.12) per share. Analysts expect a fiscal year EPS of -0.49. Cardiol focuses on developing therapies for heart disease, with its lead candidate being CardiolRxTM, a cannabidiol solution. Despite the stock's rise, it holds a Hold rating among analysts, who suggest other stocks may be better investments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments